RT Journal Article
SR Electronic
T1 Post-Mendelian genetic model in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.27.21250593
DO 10.1101/2021.01.27.21250593
A1 Picchiotti, Nicola
A1 Benetti, Elisa
A1 Fallerini, Chiara
A1 Daga, Sergio
A1 Baldassarri, Margherita
A1 Fava, Francesca
A1 Zguro, Kristina
A1 Valentino, Floriana
A1 Doddato, Gabriella
A1 Giliberti, Annarita
A1 Tita, Rossella
A1 Amitrano, Sara
A1 Bruttini, Mirella
A1 Sarno, Laura Di
A1 Iuso, Nicola
A1 Alaverdian, Diana
A1 Beligni, Giada
A1 Croci, Susanna
A1 Meloni, Ilaria
A1 Pinto, Anna Maria
A1 Gabbi, Chiara
A1 Ceri, Stefano
A1 Esposito, Antonio
A1 Pinoli, Pietro
A1 Crawley, Francis P.
A1 Frullanti, Elisa
A1 Mari, Francesca
A1 ,
A1 Gori, Marco
A1 Renieri, Alessandra
A1 Furini, Simone
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250593.abstract
AB Host genetics is an emerging theme in COVID-19 and few common polymorphisms and some rare variants have been identified, either by GWAS or candidate gene approach, respectively. However, an organic model is still missing. Here, we propose a new model that takes into account common and rare germline variants applied in a cohort of 1,300 Italian SARS-CoV-2 positive individuals. Ordered logistic regression of clinical WHO grading on sex and age was used to obtain a binary phenotypic classification. Genetic variability from WES was synthesized in several boolean representations differentiated according to allele frequencies and genotype effect. LASSO logistic regression was used for extracting relevant genes. We defined about 100 common driver polymorphisms corresponding to classical “threshold model”. Extracted genes were demonstrated to be gender specific. Stochastic rare more penetrant events on about additional 100 extracted genes, when occurred in a medium or severe background (common within the family), simulate Mendelian inheritance in 14% of subjects (having only 1 mutation) or oligogenic inheritance (in 10% having 2 mutations, in 11% having 3 mutations, etc).The combined effect of common and rare results can be described as an integrated polygenic score computed as: (nseverity − nmildness) + F (mseverity − mmildness)where n is the number of common driver genes, m is the number of driver rare variants and F is a factor for appropriately weighing the more powerful rare variants. We called the model “post-Mendelian”. The model well describes the cohort, and patients are clustered in severe or mild by the integrated polygenic scores, the F factor being calibrated around 2, with a prediction capacity of 65% in males and 70% in females. In conclusion, this is the first comprehensive model interpreting host genetics in a holistic post-Mendelian manner. Further validations are needed in order to consolidate and refine the model which however holds true in thousands of SARS-CoV-2 Italian subjects.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialnaFunding StatementMIUR project -Dipartimenti di Eccellenza 2018-2020- to Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020). Private donors for COVID-19 research. -Bando Ricerca COVID-19 Toscana-project to Azienda Ospedaliero-Universitaria Senese. Charity fund 2020 from Intesa San Paolo dedicated to the project N. B/2020/0119 - Identificazione delle basi genetiche determinanti la variabilita' clinica della risposta a COVID-19 nella popolazione italiana-. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GEN-COVID study was approved by the University Hospital of Siena Ethical Review Board (Protocol n. 16929, dated March 16, 2020). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. You may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri{at}unisi.it).